1.AbbVie's Maviret (glecaprevir/pibrentasvir) Receives European Commission Approval for Treatment-Naive Patients with Chronic Hepatitis C and Compensated Cirrhosis

Published: Aug 02, 2019 | Tags: AbbVie, Maviret, glecaprevir, pibrentasvir, Receives, European Commission, Approval, Treatment-Naïve, Patients, Chronic Hepatitis C, Compensated, Cirrhosis

2.Thermo Fisher Enters into a Collaboration with Genome Canada and OICR to Develop NGS Assays for Cancer

Published: Jul 30, 2019 | Tags:  Thermo Fisher, Enters, Collaboration, Genome Canada, OICR, Develop, NGS Assays, Cancer

3. Voluntis' Oleena Digital Application Receives FDA's Marketing Approval to Self-Manage Cancer Symptoms

Published: Aug 02, 2019 | Tags: Voluntis, Oleena, Digital Application, Receives, FDA, Marketing Approval, Self-Manage, Cancer, Symptoms

4.Mylan and Biocon Launch Ogivri (biosimilar, trastuzumab) in Australia

Published: Aug 01, 2019 | Tags: Mylan, Biocon, Launch, Ogivri, biosimilar, trastuzumab, Australia

5. Arcellx Signs a Development Evaluation and License Agreement with Pfenex for Advancing SparX Proteins

Published: Aug 01, 2019 | Tags: Arcellx, Signs, Development, Evaluation, License, Agreement, Pfenex, Advancing, SparX Proteins

6. Nektar and BMS Receive the US FDA's Breakthrough Designation for Bempegaldesleukin (NKTR-214) + Opdivo (nivolumab) to Treat Advanced Melanoma

Published: Aug 01, 2019 | Tags: Nektar, BMS, Receives, FDA, Breakthrough Designation, Bempegaldesleukin, NKTR-214, Opdivo, nivolumab, Treat, Advanced Melanoma

7.GSK's Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma

Published: Aug 01, 2019 | Tags:GSK, Nucala, mepolizumab, Receives, European Commission, Approval, Self-Administration, Severe Eosinophilic Asthma

8. Sun Pharma Reports Submission of Manufacturing and Marketing Authorization Application of Tildrakizumab in Japan

Published: Aug 01, 2019 | Tags: Sun Pharma, Reports, Submission, Manufacturing, Marketing, Authorization, Application, Tildrakizumab, Japan

9. LEO Pharma's Enstilar Foam and Taclonex Topical Suspension Receive the US FDA's Expanded Approval for Plaque Psoriasis

Published: Jul 31, 2019 | Tags: LEO Pharma, Enstilar Foam, Taclonex Topical Suspension, Receive, US, FDA, Expanded, Approval, Plaque Psoriasis

10. Exelixis Signs a Research Collaboration and Option to License Agreement with Aurigene to Discover and Develop Therapies for Cancer

Published: Aug 01, 2019 | Tags: Exelixis, Signs, Option, License, Agreement, Aurigene, Discover, Develop, Therapies, Cancer

11. Chimerix Signs an Exclusive Worldwide License Agreement with Cantex for CX-01 to Treat Acute Myeloid Leukemia

Published: Jul 31, 2019 | Tags: Chimerix, Signs, Exclusive, Worldwide, License, Agreement, Cantex, CX-01, Treat, Acute Myeloid Leukemia

13. Novartis Reports Results of Kisqali in Second Phase P-III MONALEESA-3 Study for HR+/HER2- Advanced Breast Cancer in Women

Published: Jul 31, 2019 | Tags: Novartis, Reports, Results, Kisqali, Second, Phase, P-III, MONALEESA-3, Study, HR+/HER2-, Advanced, Breast Cancer, Women

14. Pfizer Signs a License Agreement with Regenxbio for its NAV AAV9 Vector to Treat Friedreich's Ataxia

Published: Jul 31, 2019 | Tags:  Pfizer, Signs, License, Agreement, Regenxbio, NAV AAV9 Vector, Treat, Friedreich's Ataxia

15. Merck's Keytruda (pembrolizumab) Receives FDA's Approval as a Monotherapy for 1L+ Recurrent Locally Advanced or Metastatic Esophageal Cancer Expressing PD-L1 (CPS =10)

Published: Jul 31, 2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, Monotherapy, Recurrent, Locally Advanced, Metastatic Esophageal Cancer

16. Bayer's Vitrakvi (larotrectinib) Receives Health Canada Approval for Advanced Solid Tumors Harboring NTRK Gene Fusion

Published: Jul 30, 2019 | Tags: Bayer, Vitrakvi, larotrectinib, Receives, Health Canada, Approval, Advanced, Solid Tumors, Harboring, NTRK Gene Fusion

17.Gates Foundation Grants $13M to Lyndra Therapeutics for the Development of Once-Monthly Oral Contraceptive

Published: Jul 30, 2019 | Tags: Gates Foundation, Grants, $13M, Lyndra Therapeutics, Development, Once-Monthly Oral Contraceptive

18. Biogen and Alkermes Report Results of Diroximel Fumarate in P-III EVOLVE-MS-2 Study for Multiple Sclerosis

Published: Jul 30, 2019 | Tags: Biogen, Alkermes, Report, Results, Diroximel Fumarate, P-III, EVOLVE-MS-2, Study, Multiple Sclerosis

19. Bayer's Nubeqa (darolutamide) Receives the US FDA's Approval for Non-Metastatic Castration-Resistant Prostate Cancer in Men

Published: Jul 31, 2019 | Tags: Bayer, Nubeqa, darolutamide, Receives, US, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, Men

20. Merck Receives EU's CHMP Positive Opinion for its Zerbaxa (ceftolozane and tazobactam) and Keytruda (pembrolizumab) + Inlyta (axitinib) Regimen

Published: Jul 29, 2019 | Tags: Merck, Receives, EU, CHMP, Positive Opinion, Zerbaxa, ceftolozane, tazobactam, Keytruda, pembrolizumab, Inlyta, axitinib, Regimen

21. Novartis' Lucentis Receive EU's CHMP Positive Opinion for Retinopathy of Prematurity in Preterm Infants

Published: Jul 26, 2019 | Tags: Novartis, Lucentis, Receive, EU, CHMP, Positive Opinion, Retinopathy of Prematurity, Preterm Infants

22. Eli Lilly Reports Results of Verzenio (abemaciclib) in P-III MONARCH 2 for HR+ and HER2- Advanced Breast Cancer

Published: Jul 30, 2019 | Tags: Eli Lilly, Reports, Results, Verzenio, abemaciclib, P-III, MONARCH 2, HR+, HER2-, Advanced Breast Cancer

23.Exact Sciences to Merge with Genomic Health Forming a New Cancer Diagnostics Company

Published: June 29, 2019 | Tags: Exact Sciences, Merge, Genomic Health, New Cancer Diagnostics Company

24. Merck Reports Results of Keytruda (pembrolizumab) + Chemotherapy in P-III KEYNOTE-522 Study for Triple-Negative Breast Cancer

Published: Jul 29, 2019 | Tags: Merck, Reports, Results, Keytruda, pembrolizumab, CT, P-III, KEYNOTE-522, Study, Triple-Negative Breast Cancer

25.Baxter Launches PrisMax Acute Care System for Acute Kidney Injury in the US

Published: Jul 29, 2019 | Tags: Baxter, Launches, PrisMax Acute Care System, Acute Kidney Injury, US

26. Sanofi Reports Results of Zynquista (sotagliflozin) in P-III InSynchrony Program for Type2 Diabetes and Terminates Its Collaboration with Lexicon

Published: Jul 26, 2019 | Tags: Sanofi, Reports, Results, Zynquista, sotagliflozin, P-III, InSynchrony Program, Type2, Diabetes, Terminates, Collaboration, Lexicon

27. Pfizer's Upjohn Off-Patent Drug Business to Merge with Mylan to Form a New Pharmaceutical Company

Published: Jul 29, 2019 | Tags: Pfizer, Upjohn, Off-Patent, Drug, Business, Merge, Mylan, Form, New Pharmaceutical Company

28. ViiV Healthcare Reports Submission of MAA to EMA for the Combination of Cabotegravir + Rilpivirine to Treat HIV-1 Infection

Published: Jul 29, 2019 | Tags:  ViiV Healthcare, Reports, Submission, MAA, EMA, Combination, Cabotegravir, Rilpivirine, Treat, HIV-1, infection

29.Pfizer in Talks with Mylan to Merge its Off-Patent Drug Business

Published: Jul 27, 2019 | Tags: Pfizer, Talks, Mylan, Merge, Off-Patent, Drug Business